Adam Matthew Leventhal, PhD

University Professor of Population and Public Health Sciences and Psychology

Director of the Institute for Addiction Science

Image of Adam Matthew Leventhal, PhD
Is this your profile? Click to edit

Overview

Adam Leventhal, Ph.D. is a clinical psychologist, public health scientist, educator, policy advisor, and university administrator specializing in addiction. He is Founding Director of the USC Institute for Addiction Science (IAS; ias.usc.edu)–the nation’s first university-wide comprehensive academic unit devoted to understanding, reducing, and preventing addiction epidemics. IAS is a matrixed institute of 80 faculty across 10 schools and colleges across USC that provides critical infrastructure supporting the incubation and implementation of trans-discipline addiction research, education, and community engagement activities.

Dr. Leventhal is principal investigator of a research program that has received $60M in grants addressing: (1) youth use of tobacco, cannabis, and opioids; (2) health disparities in addiction; (3) science to inform public policies for regulating tobacco and other addictive consumer products; and (4) cancer and cardiovascular disease prevention. He has (co-)authored over 400 peer-reviewed scientific articles, including publications in JAMA, New England Journal of Medicine, and other widely-disseminated journals. Research led by Dr. Leventhal and his collaborators have informed numerous federal and global policies to protect youth from the dangers of tobacco and nicotine. His work has been covered the Associated Press, NBC Nightly News, New York Times, and other media outlets. In addition to science and academic administration leadership, Dr. Leventhal is an active mentor and educator to early-career professionals across the spectrum from high school students to faculty. He is an elected fellow of the American Academy of Health Behavior and American Psychological Association and recipient of awards for contributions to science and mentoring, including the American Psychological Foundation Gold Medal Award for Impact in Psychology.

Dr. Leventhal is active in translating addiction science to federal and global policy actions, having served in roles for the US Surgeon General Report Series, US Food and Drug Administration, White House Office of National Drug Control Policy, National Academy of Science, Engineering and Medicine, and World Health Organization. His personal interests include running, playing guitar, watching football, and spending time with his wonderful wife and two daughters.

#Courses
Foundations in Addiction Science
Basic Theory and Strategies in Prevention
Introduction to Health Promotion and Disease Prevention

Research Funding

  • Real World Effectiveness of Naturalistic Use of Pharmacologic Smoking Cessation Aids in US Adults.
    NIH · R01CA309463 · Aug 1, 2026 – Jul 31, 2031 · Role: Co-Principal Investigator
  • Vaping and Smoking Cessation in Intensive Longitudinal National Data
    NIH · R21DA058343 · Sep 1, 2023 – Aug 31, 2025 · Role: MPI
  • Discrimination and Racial Inequalities in Drug Use in U.S. Adults: Associations and Mechanisms
    NIH · R01DA058992 · Jun 15, 2023 – Apr 30, 2027 · Role: MPI
  • Vaping Nicotine and Cannabis Across Adolescence and Young Adulthood
    NIH · R01CA229617 · Sep 20, 2019 – Aug 31, 2025 · Role: MPI
  • Expanding Capacity for Addiction Regulatory Science Research and Mentoring
    NIH · K24DA048160 · Apr 1, 2019 – Jun 30, 2030 · Role: Principal Investigator
  • Mechanisms Linking Obsessive-Compulsive Symptoms and Tobacco Dependence
    California Tobacco-Related Disease Research Program · Jul 1, 2018 – Jun 30, 2021 · Role: Principal Investigator
  • USC Tobacco Center of Regulatory Science
    NIH · U54CA180905 · Sep 19, 2013 – Aug 31, 2028 · Role: MPI
  • Neuroendocrine Factors, Nicotine, and Behavioral Inhibition in Female Smokers
    NIH · R21DA034768 · Sep 15, 2013 – Jun 30, 2016 · Role: Principal Investigator
  • Anhedonia as a Risk Factor and Consequence of Substance Use
    NIH · R01DA033296 · Sep 15, 2012 – Jan 31, 2019 · Role: Principal Investigator
  • Mechanisms Linking Anhedonia and Tobacco Addiction
    NIH · R01DA026831 · Aug 15, 2009 – Nov 30, 2013 · Role: Principal Investigator
  • Affective and Genetic Correlates of Amphetamine Response
    NIH · K08DA025041 · Aug 1, 2009 – Jul 31, 2016 · Role: Principal Investigator

Publications

  • Reasons for Nicotine Pouch Use Among US Youth: 2025. Pediatrics. 2026 Nov 01; 158(5).. View in PubMed
  • Heated Tobacco Product Awareness and Use Among Young Adult Texas College Students During a Period of Renewed Market Activity, 2025-2026. J Community Health. 2026 Oct 15.. View in PubMed
  • Nicotine and tobacco product use among US youth in 10th and 12th grade, 2023-2025: a repeated cross-sectional study. Lancet Reg Health Am. 2027 Jan; 65:101673.. View in PubMed
  • Prevalence and Characteristics of Oral Nicotine and Tobacco Product Use among US Adults. Nicotine Tob Res. 2026 Oct 06.. View in PubMed
  • How does adolescent neurodevelopment impact substance use? The substance use neuroplasticity and peer (SNAP) model: A novel neurodevelopmental model of adolescent substance use. Neurosci Biobehav Rev. 2026 Oct 05; 192:107023.. View in PubMed
  • Estimating the Effects of Vaping Frequency on Smoking Cessation Using PATH Study Data: A Causal Forest Approach. medRxiv. 2026 Sep 07.. View in PubMed
  • A clinical call to action – How developmental translational neuroscience can catalyze adolescent substance use treatment: The example of ADAPT. Neurosci Biobehav Rev. 2026 Nov; 190:106935.. View in PubMed
  • Updated models of adolescent substance-related interference and problems (A-SIP) and measurement via the Substance-related Interference and Problems Identification Test (SIP-IT). Neurosci Biobehav Rev. 2026 Aug 11; 106898.. View in PubMed
  • Pilot randomised controlled trial of an e-cigarette and tobacco use intervention for hospitalised youth. Tob Control. 2026 Jul 31.. View in PubMed
  • E-cigarette product characteristics and packaging features and interest in e-cigarette use: Results from a randomized within-person trial nested in three prospective cohorts. Drug Alcohol Depend. 2026 Oct 01; 287:113293.. View in PubMed